Vistagen Reports Positive Preliminary Data from PALISADE-3 Open-Label Extension for Fasedienol in Social Anxiety
VTGN sits 48% above its 52-week low of $0.43.
Summary
Vistagen Therapeutics announced preliminary positive safety and exploratory efficacy data from the open-label extension of its PALISADE-3 Phase 3 study for fasedienol in social anxiety disorder, showing clinically relevant improvements and good tolerability.
Key Events · Product Development and Regulatory · VTGN
-
Positive Preliminary Data
Fasedienol showed clinically relevant improvements in social anxiety over four months in the open-label extension of the PALISADE-3 study, as measured by both clinician-administered (LSAS) and patient-reported (SPIN) scales.
-
Good Tolerability Profile
The fasedienol nasal spray was well-tolerated for up to 12 months in the open-label extension, with no new drug-related safety findings or serious adverse events identified.
-
Follows Prior Phase 3 Failure
This positive data from the open-label extension provides a new perspective after the randomized portion of PALISADE-3 failed to meet its primary endpoint in December 2025.
-
Upcoming Clinical Milestones
Topline data for the PALISADE-4 Phase 3 trial is expected in Q2 2026, and exploratory Phase 2 Repeat Dose Study data is anticipated in Q3 2026.
Analysis · VTGN · Life Sciences
This filing provides a much-needed positive update for Vistagen, especially after the randomized portion of the PALISADE-3 study failed its primary endpoint in December 2025. While the data is preliminary and from an open-label extension, it demonstrates clinically relevant improvements in both clinician-administered and patient-reported scales for social anxiety over several months, alongside a strong safety profile. This suggests fasedienol may be effective in real-world, as-needed use, a different context than the acute public speaking challenge where it previously fell short. For a company that recently disclosed substantial doubt about its ability to continue as a going concern, this positive clinical signal is critical for investor confidence and its ability to secure future financing. The market will now closely watch the upcoming PALISADE-4 topline data in Q2 2026.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 36.1% of the 1051 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.56%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, VTGN was trading at $0.64 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $26.7M. The 52-week trading range was $0.43 to $5.14. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.